孕激素受体靶向的放射性药物研究进展  

Research Progress of Radiopharmaceuticals for Progesterone Receptor Targeted Breast Cancer Imaging

作　　者：吴晓伟[1,2] 张现忠[1] 

机构地区：[1]厦门大学公共卫生学院分子影像暨转化医学研究中心分子疫苗学和分子诊断学国家重点实验室,厦门361102 [2]山东省泰安市中心医院核医学科,泰安271000

出　　处：《同位素》2017年第1期63-70,共8页Journal of Isotopes

摘　　要：分子显像技术主要有核医学显像技术、磁共振技术、光学显像技术、超声技术等。相比其他的显像技术,核医学显像技术能够显示代谢、功能和形态学信息,具有灵敏度高和可定量等优点,可在分子水平更早的发现病变。本文从单光子和正电子类显像剂的角度综述了近年来孕激素受体靶向的放射性药物研究进展及其用于诊断孕激素受体阳性乳腺癌的研究。Presently, several molecular imaging techniques including nuclear medicine imaging, magnetic resonance imaging, optical imaging and ultrasonic technology have been extensively used in clinic. Compared with other imaging techniques, nuclear medical imaging can not only display the metabolic, functional and morphological information of living subject, but also has the advantages of high sensitivity, quantitative research, and detecting lesions at earlier time. In this review, the recent progress of radiopharmaceuticals in the diagnosis of breast cancer by targeting to progesterone receptor was reviewed from the aspects of the single photon emission tomography and positron imaging agent.

关 键 词：乳腺癌 孕激素受体 单光子 正电子 显像剂 

分 类 号：R817.4[医药卫生—影像医学与核医学]